Pasithea Therapeutics -CW26KTTAWPreferred / convertible
13F holders, Q2 2026 (June 30)6holders +1
2new positions
1sold out
$0.01avg. 13F price*
At the end of Q2 2026, 6 institutions reported holding Pasithea Therapeutics -CW26 (KTTAW) in their 13F filings, up 1 from Q1 2026. 2 opened new positions and 1 sold out. The largest holders were Kepos Capital LP ($2K), Two Sigma Securities, LLC ($397) and Armistice Capital, LLC ($345).
- Company
- Pasithea Therapeutics -CW26
- CUSIP
- 70261F111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $219 |
| Exits | 1 | $150 |
All 13F filers, Q1 2026 → Q2 2026: 26,568 shares bought and 15,000 shares sold, net +11,568 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Kepos Capital LP | — | No change | 334,600 | $2K |
| Two Sigma Securities, LLC | — | Add +3.4% | 57,539 | $397 |
| Armistice Capital, LLC | — | No change | 50,000 | $345 |
| Marex Group Ltd | — | No change | 25,000 | $223 |
| Susquehanna International Group, LLP | — | New | 24,293 | $216 |
| Clear Street Group Inc. | — | New | 380 | $3 |
"% of holder's portfolio" is KTTAW's weight in each manager's 13F, not the share of Pasithea Therapeutics -CW26 the manager owns.